VaccinesArchives
PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma
Vaccines 1 min.
Therapeutic cancer vaccines have been proposed to stimulate an immune response for controlling disease progression and reducing treatment recurrence in cancer, such as pancreatic ductal adenocarcinoma (PDAC). Here, we proposed the use of PLGA/PVA nanoparticles (NPs) as the delivery component of a vaccine...
Acquired Haemophilia A and COVID-19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database.
Vaccines 1 min.
Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder commonly associated with autoimmune disorders, malignancies, infections, pregnancy, and certain medications. During the COVID-19 vaccination campaign, several case reports have documented instances of AHA occurring subsequent to SARS-CoV-2...
The role of chitosan-based nano systems in emerging vaccine technologies: current status and future expectations
Vaccines 1 min.
The multifunctional potential of chitosan, which is a natural biopolymer derived from chitin, in the field of vaccine formulation will be explored in this review. Firstly, how this unique chemically versatile structure of chitosan allows scientists to tailor nano systems that precisely control the delivery...
Working toward a single-dose vaccine for rabies post-exposure prophylaxis
Vaccines 1 min.
Rabies is almost universally fatal if not treated before symptoms appear. Fortunately, post-exposure prophylaxis (PEP) is a nearly 100% effective treatment when started soon after rabies exposure. Nevertheless, rabies causes approximately 59,000 deaths annually, predominantly in rural parts of low- and...
